Expansion Opportunity MegaGen ownership and recent nearly $1M investment to expand Corona manufacturing infrastructure indicates a commitment to scale production capacity and supply stability for Waterlase and Epic laser systems, presenting a sales opportunity for upgraded systems, accessories, and long-term service contracts.

Laser Leadership BIOLASE remains a global leader in dental lasers with a broad ecosystem including Waterlase all-tissue lasers and Epic diode lasers, suggesting potential for cross-sell of consumables, training subscriptions, and integrated practice growth solutions to expand adoption among existing customers.

Educational Momentum Active focus on clinical training, continuing education, and case-based programs positions BIOLASE to upsell advanced training packages, certified protocols, and regional seminars to boost practitioner proficiency and laser utilization.

Industry Partnerships Strategic alignment with MegaGen Implant and a shift toward U.S. support through MegaGen America indicates a channel-rich approach; opportunities exist for joint marketing, bundled offerings, and co-branded solutions to accelerate market penetration in clinics.

Financial and Coverage Signals Past financial moves include Chapter 11 proceedings in 2024 and subsequent acquisition by MegaGen in 2025, followed by performance in Q2 2024 with strong consumables revenue and recurring subscriptions; potential sales focus on recurring revenue models, service plans, and consumable pipelines for existing and new customers.